Azeliragon, a RAGE Inhibitor, in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase Ib/II CAN-201 NDG Trial Design.

Jose Manuel Sepulveda, Manuel Valiente,Maria Angeles Vaz-Salgado,Estela Pineda, Maria Martinez-Garcia, Maria Ruiz Vico, Gabriel Velilla, Manuel Alejandro Mazariegos,Izaskun Valduvieco,Maria Castro-Henriques, Laia Cano, Stephen Garrett Marcus

Journal of Clinical Oncology（2024）

Cited 0|Views1

No score

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined